Cereno Scientific (DB:4A1) - Hisse Senedi Fiyatı, Haberler ve Analizler

4A1 Stoklara Genel Bakış

Klinik aşama biyoteknoloji şirketi olan Cereno Scientific AB (publ), dünya çapında kardiyovasküler ve nadir hastalıkları tedavi etmek için terapötikler geliştirmektedir. Daha fazla detay

4A1 temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	2/6
Temettüler	0/6

Risk Analizi

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

1 yıldan az nakit akışı var

Kazançlar son 5 yılda yılda 49.7% oranında azaldı

Hissedarlar geçen yıl sulandırıldı

Cereno Scientific AB (publ) Rakipler

Heidelberg Pharma

XTRA:HPHA

€105.8m

2invest

XTRA:2INV

€62.7m

Formycon

XTRA:FYB

€857.2m

Biotest

XTRA:BIO3

€1.3b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Cereno Scientific
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	SEK 0.43
52 Haftanın En Yüksek Seviyesi	SEK 0.79
52 Haftanın En Düşük Seviyesi	SEK 0.29
Beta	0.35
11 Aylık Değişim	-10.22%
3 Aylık Değişim	-25.80%
1 Yıllık Değişim	-0.23%
33 Yıllık Değişim	-8.37%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	50.35%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	4A1	DE Biotechs	DE Pazar
7D	2.7%	0.8%	0.8%
1Y	-0.2%	-18.3%	8.6%

Getiri vs. Endüstri: 4A1 geçen yıl % -18.3 oranında getiri sağlayan German Biotechs sektörünü aştı.

Getiri vs Piyasa: 4A1 geçen yıl % 8.6 oranında getiri sağlayan German Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is 4A1's price volatile compared to industry and market?
4A1 volatility
4A1 Average Weekly Movement	11.6%
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: 4A1 hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: 4A1 'nin haftalık oynaklığı ( 12% ) geçen yıl boyunca sabit kaldı, ancak hala German hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2012	5	Sten Sorensen	www.cerenoscientific.com

Klinik aşama biyoteknoloji şirketi Cereno Scientific AB (publ), dünya çapında kardiyovasküler ve nadir hastalıkları tedavi etmek için terapötikler geliştirmektedir. Şirketin öncü ilaç adayı, nadir görülen bir hastalık olan pulmoner arteriyel hipertansiyonun tedavisi için faz II klinik çalışmasında olan bir ürün adayı olan CS1'in yanı sıra basınç düşürücü, tersine yeniden şekillendirme, anti-enflamatuar, anti-fibrotik ve antitrombotik özelliklere sahip bir epigenetik modülatör görevi gören bir histon deasetilaz (HDAC) inhibitörüdür. Preklinik ilaç adayları, kardiyovasküler hastalıkların tedavisi için klinik öncesi aşamada olan CS585 ve CS014'ü içermektedir.

Cereno Scientific AB (publ) Temel Bilgiler Özeti

Cereno Scientific'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
4A1 temel i̇stati̇sti̇kler
Piyasa değeri	€121.70m
Kazançlar(TTM)	-€7.03m
Gelir(TTM)	€7.52m

16.2x

P/S Oranı

-17.3x

F/K Oranı

4A1 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
4A1 gelir tablosu (TTM)
Gelir	SEK 86.75m
Gelir Maliyeti	SEK 0
Brüt Kâr	SEK 86.75m
Diğer Giderler	SEK 167.87m
Kazançlar	-SEK 81.12m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

Feb 25, 2025

Hisse başına kazanç (EPS)	-0.29
Brüt Marj	100.00%
Net Kâr Marjı	-93.51%
Borç/Özkaynak Oranı	39.2%

4A1 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

4A1 Stoklara Genel Bakış

Risk Analizi

Cereno Scientific AB (publ) Rakipler

XTRA:HPHA

€105.8m

XTRA:2INV

€62.7m

XTRA:FYB

€857.2m

XTRA:BIO3

€1.3b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Cereno Scientific Announces Initiation of Multiple Ascending Dose (MAD) Part of Phase I Trial of the Novel HDAC Inhibitor CS014

Cereno Scientific AB (publ) to Report Q2, 2025 Results on Aug 27, 2025

Cereno Scientific AB (publ) Selects Rare Disease Idiopathic Pulmonary Fibrosis as the Initial Target Indication for Novel HDACi CS014

Cereno Scientific AB (publ) Announces New Preclinical Data Demonstrates Dose Dependent Positive Impact on Reversal of Pulmonary Vascular Remodeling

Cereno Scientific AB Announces Changes in the Nomination Committee's Composition for the Annual General Meeting 2025

No independent directors

Recent updates

Cereno Scientific Announces Initiation of Multiple Ascending Dose (MAD) Part of Phase I Trial of the Novel HDAC Inhibitor CS014

Cereno Scientific AB (publ) to Report Q2, 2025 Results on Aug 27, 2025

Cereno Scientific AB (publ) Selects Rare Disease Idiopathic Pulmonary Fibrosis as the Initial Target Indication for Novel HDACi CS014

Cereno Scientific AB (publ) Announces New Preclinical Data Demonstrates Dose Dependent Positive Impact on Reversal of Pulmonary Vascular Remodeling

Cereno Scientific AB Announces Changes in the Nomination Committee's Composition for the Annual General Meeting 2025

No independent directors

Cereno Scientific AB Announces New Preclinical Data for Cereno Scientific's Novel IP Receptor Agonist CS585 Presented at ESC Congress 2024

Cereno Scientific Receives Orphan Medicinal Product Designation in the Eu for Cs1 in Rare Disease Pulmonary Arterial Hypertension

Cereno Scientific AB (publ), Annual General Meeting, Jun 17, 2025

Cereno Scientific Expands Patent Protection for PAH Drug Candidate CS1's Third Patent Family in Brazil

First Subject Dosed in Cereno Scientifics First-In-Human Phase I Trial of Novel Hdac Inhibitor Cs014

Cereno Scientific Receives Approval from, EMA to Initiate First-In-Human Phase I Trial with Novel Epigenetic HDAC Inhibitor, CS014

Cereno Scientific AB (publ) to Report Q1, 2025 Results on May 22, 2025

Cereno Scientific AB (Publ) Announces Nomination Committee Appointments Ahead of Annual General Meeting 2025

Cereno Scientific AB (publ), Annual General Meeting, Apr 16, 2024

Cereno Scientific AB (Publ) Approves Election of New Directors

Cereno Scientific AB Submits Clinical Trial Application (CTA) for First-In-Human Phase I Study with Novel Epigenetic HDACi Drug Candidate CS014

Full year 2023 earnings released: kr0.21 loss per share (vs kr0.20 loss in FY 2022)

Cereno Scientific Announces A Study Protocol Presented for the FDA Approved Expanded Access Program for CS1 in PAH

Cereno Scientific Appoints Don De Bethizy as Board of Directors

Cereno Scientific Publishes Update and Study Protocol for the FDA Approved Expanded Access Program for CS1 in PAH

Cereno Scientific Reports One New Patient Enrolled, One Additional Patient Randomized, and One Additional Patient Completed in the Phase II Study of CS1 in PAH

Full year 2023 earnings released: kr0.21 loss per share (vs kr0.20 loss in FY 2022)

Cereno Scientific Reports Progress of Expanded Access Program and Announces Timeline Adjustment in the Phase II Study of CS1 in PAH

New minor risk - Market cap size

Cereno Scientific AB Appoints Rahul Agrawal as Chief Medical Officer and Head of R&D

Cereno Scientific AB (publ) Appoints Megha Ranjan as Project Director to Strengthen Business Capabilities

Cereno Scientific AB Appoints Julia Fransson as Director of Business Development

Cereno Scientific Receives Expanded Access by the FDA to Drug Candidate CS1 for Rare Disease Pulmonary Arial Hypertension

Cereno Scientific Strengthens R&D with Recruitment of Tatiane Abreu Dall'Agnol as Medical Director

Cereno Scientific AB Confirms New Clinic Activated in the Phase II Study of Drug Candidate CS1 in Rare Disease PAH

Cereno Scientific AB (publ) to Report Q3, 2024 Results on Nov 21, 2024

Cereno Scientific's Novel HDACi CS014 Has Potential to Become an Effective Antithrombotic Therapy in Patients with A High Risk of Thrombotic Events as Presented at the ASH Meeting

Cereno Scientific Announces New Preclinical Data Concludes That Drug Candidate CS585

Cereno Scientific Completes Preclinical Safety Program for Innovative Drug Candidate CS014 Targeting Thrombosis Prevention and Reaches A Major Preparatory Milestone Towards the Phase I Study

Cereno Scientific Obtains First Patent in India for Drug Candidate Cs1 Through Its Third Patent Family

Cereno Scientific AB (Publ) Move to Request “Compassionate Use” of CS1 for Treatment of Patients with Rare Disease PAH

Third quarter 2023 earnings released

Cereno Scientific Reports Significant Progress and A Time Time Adjustment in the Phase II Study of CS1 in Rare Disease PAH

Cereno Scientific AB (publ) Appoints Jeppe Øvlesen as a New Board Member

Cereno Scientific AB (Publ) Reports Positive Results from the Data Quality Control Review Initiative in the Phase II Study of CS1 in Rare Disease Pul Arterial Hypertension (PAH)

Cereno Scientific Announces Appointments to the Nomination Committee Ahead of the Annual General Meeting 2024

New major risk - Shareholder dilution

Second quarter 2023 earnings released

Cereno Scientific to Open Two New Clinics to Complete Patient Recruitment in the Phase II Study of CS1 in Pah

Cereno Scientific AB (Publ) Appoints Eva Jagenheim as Chief Financial Officer

Cereno Scientific Reports Positive Data from Patient Case Study

Chairperson recently bought €68k worth of stock

Cereno Scientific Reports an Investigator-Initiated Patient Case Study from the Ongoing Phase II Study of CS1 in PAH

Cereno Scientific AB (publ), Annual General Meeting, Jun 03, 2024

Cereno Scientific Shares Progress Update in the Phase II Study with Drug Candidate CS1 in the Rare Disease PAH

Cereno Scientific's Phase II Study in the Rare Disease PAH Reports Two Patients Successfully Completed the Treatment Period with Drug Candidate CS1

Full year 2022 earnings released: kr0.20 loss per share (vs kr0.15 loss in FY 2021)

Full year 2022 earnings released: kr0.26 loss per share (vs kr0.15 loss in FY 2021)

Cereno Scientific AB (publ) Reports Progress with CS1 Phase II Study in Pulmonary Arterial Hypertension

Cereno Scientific AB (publ) to Report Nine Months, 2023 Results on Nov 17, 2023

Cereno Scientific AB (Publ) Appoints Etienne Adriansen to Chief Business Officer, as of March 1, 2023

Cereno Scientific Announces Changes in the Executive Management Team

Cereno Scientific Reports Six Activated Clinical Sites and Updated Timeline in the Phase II Study in PAH with Drug Candidate CS1

Cereno Scientific AB (Publ) Announces Appointment of Nomination Committee